Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 7 | 2021 | 671 | 2.540 |
Why?
|
| Heart Failure | 12 | 2021 | 1969 | 2.350 |
Why?
|
| Heart-Assist Devices | 4 | 2021 | 485 | 1.760 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 278 | 1.200 |
Why?
|
| Cardiology | 2 | 2020 | 272 | 1.100 |
Why?
|
| Patient Selection | 2 | 2020 | 676 | 1.090 |
Why?
|
| Registries | 4 | 2019 | 1810 | 0.850 |
Why?
|
| Stroke Volume | 3 | 2020 | 513 | 0.820 |
Why?
|
| Waiting Lists | 2 | 2019 | 228 | 0.740 |
Why?
|
| BK Virus | 1 | 2019 | 15 | 0.720 |
Why?
|
| Population Health | 1 | 2020 | 46 | 0.710 |
Why?
|
| Patient Advocacy | 1 | 2019 | 66 | 0.680 |
Why?
|
| Viremia | 1 | 2019 | 132 | 0.680 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 200 | 0.670 |
Why?
|
| Triage | 1 | 2020 | 203 | 0.620 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 150 | 0.620 |
Why?
|
| Organizational Objectives | 1 | 2017 | 74 | 0.600 |
Why?
|
| Health Policy | 1 | 2020 | 333 | 0.600 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2018 | 85 | 0.600 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 101 | 0.590 |
Why?
|
| Betacoronavirus | 1 | 2020 | 254 | 0.590 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 105 | 0.580 |
Why?
|
| Heart Diseases | 1 | 2020 | 341 | 0.580 |
Why?
|
| Cardiovascular System | 1 | 2017 | 127 | 0.550 |
Why?
|
| Mentors | 1 | 2017 | 166 | 0.540 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 867 | 0.540 |
Why?
|
| Mentoring | 1 | 2017 | 101 | 0.540 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 387 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 348 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.510 |
Why?
|
| Health Services Research | 1 | 2017 | 385 | 0.490 |
Why?
|
| Quality Improvement | 2 | 2020 | 963 | 0.460 |
Why?
|
| Biomedical Research | 1 | 2017 | 612 | 0.400 |
Why?
|
| Medication Adherence | 1 | 2016 | 556 | 0.400 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 299 | 0.390 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 102 | 0.300 |
Why?
|
| Humans | 19 | 2021 | 118974 | 0.270 |
Why?
|
| United States | 6 | 2019 | 12555 | 0.260 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 1200 | 0.200 |
Why?
|
| Insurance, Health | 2 | 2021 | 244 | 0.200 |
Why?
|
| Pericarditis | 1 | 2020 | 9 | 0.190 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2674 | 0.190 |
Why?
|
| Cryptococcus neoformans | 1 | 2020 | 18 | 0.190 |
Why?
|
| Female | 11 | 2020 | 61565 | 0.190 |
Why?
|
| Cryptococcosis | 1 | 2020 | 23 | 0.190 |
Why?
|
| Cardiologists | 1 | 2020 | 40 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2020 | 9342 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 4596 | 0.170 |
Why?
|
| Adult | 7 | 2020 | 31512 | 0.170 |
Why?
|
| Male | 10 | 2020 | 57801 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2020 | 3057 | 0.170 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 127 | 0.160 |
Why?
|
| Viral Load | 1 | 2019 | 419 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 67 | 0.160 |
Why?
|
| Community Health Services | 1 | 2019 | 212 | 0.150 |
Why?
|
| Long-Term Care | 1 | 2018 | 74 | 0.150 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 43 | 0.150 |
Why?
|
| Professional Competence | 1 | 2017 | 91 | 0.150 |
Why?
|
| Patient Safety | 1 | 2020 | 281 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 369 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2018 | 5116 | 0.140 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 69 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 496 | 0.140 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 12 | 0.140 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 191 | 0.140 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 46 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6561 | 0.130 |
Why?
|
| Career Choice | 1 | 2017 | 192 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1384 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 261 | 0.130 |
Why?
|
| Aged | 6 | 2020 | 19657 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 195 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 554 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2016 | 237 | 0.120 |
Why?
|
| Dyspnea | 1 | 2015 | 201 | 0.120 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2014 | 42 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2019 | 654 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2017 | 394 | 0.120 |
Why?
|
| Survival Rate | 1 | 2018 | 1720 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 992 | 0.110 |
Why?
|
| Medicaid | 1 | 2017 | 411 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1166 | 0.110 |
Why?
|
| Medicare | 1 | 2018 | 663 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2016 | 1267 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 497 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1355 | 0.100 |
Why?
|
| Curriculum | 1 | 2017 | 910 | 0.100 |
Why?
|
| Logistic Models | 1 | 2016 | 1901 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1474 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2995 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2018 | 12978 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2235 | 0.080 |
Why?
|
| Time Factors | 2 | 2016 | 6412 | 0.080 |
Why?
|
| Middle Aged | 5 | 2020 | 27617 | 0.070 |
Why?
|
| Risk Factors | 1 | 2020 | 9000 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 4708 | 0.070 |
Why?
|
| Hospitalization | 1 | 2014 | 1785 | 0.070 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 10 | 0.050 |
Why?
|
| Fluconazole | 1 | 2020 | 16 | 0.050 |
Why?
|
| Health Services Misuse | 1 | 2020 | 36 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2020 | 134 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2020 | 165 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 556 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 374 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2017 | 125 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 490 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 208 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 106 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1244 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1636 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 827 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 551 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 749 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 940 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 702 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 3443 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3588 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 6471 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 10793 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 18480 | 0.010 |
Why?
|